Jakavi 5mg Tablet
Prescription Required
Product introduction
Jakavi 5mg Tablet is used in the treatment of chronic idiopathic myelofibrosis and Polycythemia vera.
Jakavi 5mg Tablet is used to treat different types of cancer
Jakavi 5mg Tablet is used to treat different types of cancer
Uses of Jakavi Tablet
- Polycythemia vera
- Chronic idiopathic myelofibrosis
Benefits of Jakavi Tablet
In Polycythemia vera
Polycythemia vera is a type of blood cancer that causes excessive production of red blood cells. This may lead to blood clot formation and lead to other serious health issues. Jakavi 5mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. It is an effective, yet very toxic medicine and you should discuss the risks and benefits with your doctor. Avoid drinking alcohol or smoking while having this treatment and drink plenty of water to stay hydrated.
In Chronic idiopathic myelofibrosis
Chronic idiopathic myelofibrosis is a long-term problem that causes fibrous, or scar, tissue to form in the bone marrow. The scarring means the bone marrow can't work normally and produces fewer red blood cells and usually too many white blood cells. Jakavi 5mg Tablet kills or stops the growth of cancer cells and also prevents the multiplication of cancer cells. You may experience some bothersome side effects. Discuss with your doctor if you have any doubts.
Side effects of Jakavi Tablet
Most side effects do not require any medical attention and disappear as your body adjusts to the medicine. Consult your doctor if they persist or if you’re worried about them
Common side effects of Jakavi
- Headache
- Dizziness
- Low blood platelets
- Anemia (low number of red blood cells)
How to use Jakavi Tablet
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Jakavi 5mg Tablet may be taken with or without food, but it is better to take it at a fixed time.
Safety advice
Alcohol
SAFE
Consuming alcohol with Jakavi 5mg Tablet does not cause any harmful side effects.
Pregnancy
CONSULT YOUR DOCTOR
Jakavi 5mg Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Breast feeding
CONSULT YOUR DOCTOR
Jakavi 5mg Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Driving
UNSAFE
Jakavi 5mg Tablet may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Kidney
CAUTION
Jakavi 5mg Tablet should be used with caution in patients with kidney disease. Dose adjustment of Jakavi 5mg Tablet may be needed. Please consult your doctor.
Use of Jakavi 5mg Tablet is not advised in patients with moderate to severe kidney disease.
Use of Jakavi 5mg Tablet is not advised in patients with moderate to severe kidney disease.
Liver
CAUTION
Jakavi 5mg Tablet should be used with caution in patients with liver disease. Dose adjustment of Jakavi 5mg Tablet may be needed. Please consult your doctor.
All substitutes
For informational purposes only. Consult a doctor before taking any medicines.
No substitutes found for this medicine
Quick tips
- Take it with or without food, preferably at the same time each day.
- It may cause dizziness and headaches. Do not drive or do anything that requires mental focus until you know how it affects you.
- Use a reliable contraceptive method to prevent pregnancy while you are taking this medicine.
- Your doctor may get regular blood tests done to monitor your blood cells, liver and kidney function, and lipid levels during treatment with this medicine.
- Inform your doctor immediately if you notice any signs of infection such as fever, sore throat or rash.
- Do not stop taking Jakavi 5mg Tablet without talking to your doctor first.
Fact Box
Chemical Class
Pyrrolo[2,3-d]pyrimidines Derivative
Habit Forming
No
Therapeutic Class
ANTI NEOPLASTICS
Action Class
Tyrosine kinase inhibitors
Patient concerns
Want to share the information?
Disclaimer:
Tata 1mg's sole intention is to ensure that its consumers get information that is expert-reviewed, accurate and trustworthy. However, the information contained herein should NOT be used as a substitute for the advice of a qualified physician. The information provided here is for informational purposes only. This may not cover everything about particular health conditions, lab tests, medicines, all possible side effects, drug interactions, warnings, alerts, etc. Please consult your doctor and discuss all your queries related to any disease or medicine. We intend to support, not replace, the doctor-patient relationship.References
- Briggs GG, Freeman RK, editors. A Reference Guide to Fetal and Neonatal Risk: Drugs in Pregnancy and Lactation. 10th ed. Philadelphia, PA: Wolters Kluwer Health; 2015. p. 1240.
- Ruxolitinib. Greenville, North Carolina: DSM Pharmaceuticals, Inc.; 2011. [Accessed 24 Jan. 2019] (online) Available from:
- Ruxolitinib. Wilmington, Delaware: Incyte Corporation; 2011 [revised Dec. 2014]. [Accessed 27 Mar. 2019] (online) Available from:
- Ruxolitinib. Camberley, Surrey: Novartis Pharmaceuticals UK Ltd; 2012 [revised 22 May 2018]. [Accessed 27Mar. 2019] (online) Available from:
Marketer details
Name: Novartis India Ltd
Address: Sandoz House, Shiv Sagar Estate, Worli Mumbai -400 018, India
Country of origin: Switzerland
Lab tests offered by us
Related/Popular tests
MRP
₹21489
Inclusive of all taxes
10.0 tablets in 1 strip
SOLD OUT
Variants (2)
Notify me